Literature DB >> 19393105

Monitoring respiratory disease severity in cystic fibrosis.

Jane C Davies1, Eric Wfw Alton.   

Abstract

Measurements of disease severity provide a guide for the physician to tailor therapies, for the patient and family to gauge progress, and are required for clinical trials. For many respiratory diseases, including cystic fibrosis, sensitive, noninvasive measurements are few, and some of those that are available are applicable only to certain subgroups of patients or lack sufficient sensitivity. We discuss currently available measurements in 4 groups: physiology, infection, inflammation, and radiology. For each group we highlight strengths and weaknesses, ask how we could improve upon these, and provide details of alternative methods.

Entities:  

Mesh:

Year:  2009        PMID: 19393105     DOI: 10.4187/aarc0493

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  14 in total

1.  Spirometry-related pain and distress in adolescents and young adults with cystic fibrosis: the role of acceptance.

Authors:  Annabelle Casier; Liesbet Goubert; Tine Vervoort; Marleen Theunis; Danielle Huse; Frans De Baets; Dirk Matthys; Geert Crombez
Journal:  Pain Res Manag       Date:  2013-08-28       Impact factor: 3.037

2.  Early detection of lung function decrements in children and adolescents with cystic fibrosis using new reference values.

Authors:  Angela Zacharasiewicz; Sabine Renner; Flora Haderer; Michael Weber; Eleonore Dehlink; Zsolt Szepfalusi; Thomas Frischer
Journal:  Wien Klin Wochenschr       Date:  2017-03-09       Impact factor: 1.704

3.  Microstructural alterations of sputum in cystic fibrosis lung disease.

Authors:  Gregg A Duncan; James Jung; Andrea Joseph; Abigail L Thaxton; Natalie E West; Michael P Boyle; Justin Hanes; Jung Soo Suk
Journal:  JCI Insight       Date:  2016-11-03

4.  Evaluation of surrogate measures of pulmonary function derived from electrical impedance tomography data in children with cystic fibrosis.

Authors:  Peter A Muller; Jennifer L Mueller; Michelle Mellenthin; Rashmi Murthy; Michael Capps; Brandie D Wagner; Melody Alsaker; Robin Deterding; Scott D Sagel; Jordana Hoppe
Journal:  Physiol Meas       Date:  2018-04-26       Impact factor: 2.833

5.  A Compositional Analysis of Physical Activity, Sedentary Time, and Sleep and Associated Health Outcomes in Children and Adults with Cystic Fibrosis.

Authors:  Mayara S Bianchim; Melitta A McNarry; Anne Holland; Narelle S Cox; Julianna Dreger; Alan R Barker; Craig A Williams; Sarah Denford; Kelly A Mackintosh
Journal:  Int J Environ Res Public Health       Date:  2022-04-23       Impact factor: 4.614

6.  Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study.

Authors:  David Taylor-Robinson; Margaret Whitehead; Finn Diderichsen; Hanne Vebert Olesen; Tania Pressler; Rosalind L Smyth; Peter Diggle
Journal:  Thorax       Date:  2012-05-03       Impact factor: 9.139

7.  Joint modelling of repeated measurements and time-to-event outcomes: flexible model specification and exact likelihood inference.

Authors:  Jessica Barrett; Peter Diggle; Robin Henderson; David Taylor-Robinson
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2014-04-08       Impact factor: 4.488

8.  Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis.

Authors:  Fernando Augusto de Lima Marson; Tais Daiene Russo Hortencio; Katia Cristina Alberto Aguiar; Jose Dirceu Ribeiro
Journal:  BMC Pulm Med       Date:  2015-01-15       Impact factor: 3.317

9.  Symptoms of depression impact the course of lung function in adolescents and adults with cystic fibrosis.

Authors:  Astrid Fidika; Marion Herle; Lutz Goldbeck
Journal:  BMC Pulm Med       Date:  2014-12-16       Impact factor: 3.317

10.  Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity.

Authors:  Joseph Finkelstein; Eunme Cha; Steven M Scharf
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.